Global Age-Related Macular Degeneration Market Forecast Report by Disease Type (Dry Age-Related Macular Degeneration Market, Wet Age-Related Macular Degeneration Market) Product (Eylea, Lucentis, Beovu, Others) Distribution Channel (Hospital Pharmacy, Specialty Pharma, Online Pharmacy) Countries and Company Analysis, 2024-2032
Buy NowAge-Related Macular Degeneration Market Analysis
The market for Global Age-Related Macular Degeneration is predicted to reach US$ 19.53 billion in 2032, increasing at a compound annual growth rate of 6.94% from 2024 to 2032, while it was estimated to reach US$ 10.68 billion by 2023. The age-related macular degeneration market is mainly being driven by the growing elderly population, who are more susceptible to structural and blood flow abnormalities that lead to the destruction of macula cells. Furthermore, the market is growing due to the rising incidence of a number of associated risk factors, including genetic predisposition, high blood pressure, smoking, prolonged exposure to blue light, obesity, and consumption of a diet high in saturated fat.
Age-Related Macular Degeneration Market Outlook
In developed nations, age-related macular degeneration, or AMD, is the primary cause of blindness in older adults. It is an age-related eye condition that gradually impairs central vision, which is necessary for reading, driving, identifying faces, and seeing colour in the environment. As AMD progresses, central vision loss results, impairing the quality of life for many people who cannot read, write, perceive colour, or distinguish detail. Even though the precise functional etiology of AMD is still unknown, recent advancements in genetic technologies have allowed for the identification of several variants that have been demonstrated to have particular connections with AMD.
The middle portion of the retina, the macula, gradually deteriorates with AMD, resulting in loss of central vision. Based on its clinical characteristics, such as drusen, aberrant pigmentation, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV), AMD can be categorized as early, moderate, or late.
Additionally, AMD can be classified as wet (exudative or neovascular) or dry (atrophic or non-neovascular).
The World Health Organization (WHO) estimates that in 2020, age-related macular degeneration will impact 196 million individuals worldwide, with about 10.4 million cases of moderate-to severe vision impairment.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 10.68 Billion |
|
Market Forecast in 2032 |
US$ 19.53 Billion |
|
Market Growth Rate (2024-2032) |
6.94% |
Growth Factors of the Age-Related Macular Degeneration Market
Population Aging and Rising AMD Incidence
The market for age-related macular degeneration (AMD) is significantly impacted by the global increase in the population over 50. Since age is the primary risk factor for AMD, the world's aging population contributes to the condition's rising prevalence. This change in demographics is driving the market, driving up demand for AMD therapies and diagnostics. The increasing number of potential patients highlights the need for more research and development to address the particular needs of this senior group.
Technological Advancement in Medical Diagnostics and Therapy
AMD is primarily driven by continuous advancements in diagnostic technology, including as optical coherence tomography (OCT) and fundus imaging. These tools allow for accurate diagnosis, early identification, and tracking of AMD progression, all of which lead to timely intervention. In addition, improvements in treatment strategies—more especially, the success of anti-VEGF drugs—have completely changed the area of AMD management. The advent of gene therapies and regenerative medicine broadens the spectrum of treatments that are accessible and creates new opportunities for targeted and individualized care. The continued advancement of these technologies promotes the effectiveness and efficiency of AMD diagnosis and treatment, hence bolstering market expansion.
North America Age-Related Macular Degeneration Market
The United States, Canada, and Mexico are the regional markets for North America Refrigerated Macular Degeneration (AMD) market in North America are the increasing prevalence of the disease among the elderly population, the involvement of significant market players, and increased R&D efforts. Additionally, this information was shared by the American Macular Degeneration Foundation (AMDF) in the US to alert eye care providers and AMD patients to the possible risk.
Advanced AMD is the leading cause of permanent blindness and visual impairment worldwide. Consequently, the market is expanding along with AMD's load. Additionally, according to the Canadian Ophthalmological Society, wet age-related macular degeneration is one of the main causes of visual loss in persons over 65.
The vision-threatening form of AMD, known as late AMD, is thought to affect 1.5 million Americans, according to the American Academy of Ophthalmology. 18.3 million Americans are thought to have early AMD.
AMD is more common as people age. Roughly 3 out of 10 Americans over the age of 80 have early AMD, and 1 out of 10 have late AMD.
Age-Related Macular Degeneration Market Company Overview
- Hoffmann - La Roche Ltd., Bayer AG, Abbvie, GSK Plc, Novartis AG, Regeneron Pharmaceuticals, Bausch Health Companies Inc., Alimera Sciences Inc., are among the industry leaders in the Global Age-Related Macular Degeneration Market.
Global Age-Related Macular Degeneration Market News
In March 2024, A commercial alliance agreement was inked by Sumitomo Corporation Roche Pharma India introduced Vabysmo (faricimab) to treat diabetic macular edema (DME) and neovascular or "wet" age-related macular degeneration (nAMD). This new medicine marks the pharma major's first entry into the ophthalmology market. AMD and DME are the two main causes of visual loss in the world. Claiming to be a dual pathway inhibitor, the company named it Vabysmo and said it inhibited two disease processes linked to different retinal disorders that can impair vision.
In August 2024, Astellas said that IZERVAYTM (avacincaptad pegol intravitreal solution) has been approved by the US Food and Drug Administration (FDA) to treat geographic atrophy (G.A.) secondary to AMD. The approval is effective as of August 4. In two Phase III pivotal studies using a Novel Complement C5 Inhibitor, only IZERVAY demonstrated a statistically significant reduction (p<0.01) in the rate of G.A. progression among all approved G.A. therapies for the Primary Endpoint at Month 12 its supply locations, minimize food loss, and lower greenhouse gas emissions while promoting a steady supply of food items.
Disease Type – Market breakup in 2 viewpoints:
- Dry Age-Related Macular Degeneration Market
- Wet Age-Related Macular Degeneration Market
Product – Market breakup in 4 viewpoints:
- Eylea
- Lucentis
- Beovu
- Others
Distribution channel – Market breakup in 2 viewpoints:
- Hospital Pharmacy
- Specialty Pharma
- Online Pharmacy
Country – Market breakup in 25 viewpoints:
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand
• Latin America
Brazil
• Brazil
• Mexico
• Argentina
Middle East & Africa
• South Africa
• Saudi Arabia
• United Arab Emirates
All the Key players have been covered from 4 Viewpoints:
- Overview
- Recent Development & Strategies
- Product Portfolio
- Financial Insights
Company Analysis:
- Hoffmann - La Roche Ltd.
- Bayer AG
- Abbvie
- GSK Plc
- Novartis AG
- Regeneron Pharmaceuticals
- Bausch Health Companies Inc.
- Alimera Sciences Inc.
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Billion |
| Segment Covered |
Disease Type, Product, Distribution Channel and Countries |
| Countries Covered |
|
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Key Questions Answered in This Report:
• How big is the Age-Related Macular Degeneration industry?
• What is the Age-Related Macular Degeneration industry growth rate?
• Who are the key players in Age-Related Macular Degeneration industry?
• What are the factors driving the Age-Related Macular Degeneration industry?
• Which Region held the largest market share in the Age-Related Macular Degeneration industry?
Customization Services available
• Analysis of Market Size and Its Segments
• More Company Profiles (Upto 10 without any additional cost):
• Additional Countries (Other than mentioned Countries):
• Region/Country Specific Reports:
• Market Entry Strategy:
• Region-Specific Market Dynamics:
• Regional Market Share Analysis:
• Trade Analysis:
• Production Insights:
• Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
• Talk to our analysts to get more precious information on the current market trends.
• Include more countries and segments and customize the report based on the final requirement.
• Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
• Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Age-Related Macular Degeneration Market
6. Market Share
6.1 Disease Type
6.2 Product
6.3 Distribution Channel
6.4 Country
7. Disease Type
7.1 Dry Age-Related Macular Degeneration Market
7.2 Wet Age-Related Macular Degeneration Market
8. Product
8.1 Eylea
8.2 Lucentis
8.3 Beovu
8.4 Others
9. Distribution Channel
9.1 Hospital Pharmacy
9.2 Specialty Pharma
9.3 Online Pharmacy
10. Country
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Thailand
10.3.7 Malaysia
10.3.8 Indonesia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 South Africa
10.5.2 Saudi Arabia
10.5.3 UAE
11. Porter’s Five Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Key Players Analysis
13.1 F. Hoffmann - La Roche Ltd.
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Financial Insight
13.2 Bayer AG
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Financial Insight
13.3 Abbvie
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Financial Insight
13.4 GSK Plc
13.4.1 Overview
13.4.2 Recent Development
13.4.3 Financial Insight
13.5 Novartis AG
13.5.1 Overview
13.5.2 Recent Development
13.5.3 Financial Insight
13.6 Regeneron Pharmaceuticals
13.6.1 Overview
13.6.2 Recent Development
13.6.3 Financial Insight
13.7 Bausch Health Companies Inc.
13.7.1 Overview
13.7.2 Recent Development
13.7.3 Financial Insight
13.8 Alimera Sciences Inc.
13.8.1 Overview
13.8.2 Recent Development
13.8.3 Financial Insight
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com